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Purpose: To develop a sensitive and rapid method for the simultaneous determination of curcumin and 
piperine in human plasma.  
Methods: The method was based on high-performance liquid chromatography (HPLC) with electrospray 
ionization tandem mass spectrometer (ESI-MS/MS) detection in positive ionization mode. The analytes 
and internal standard were isolated from acidified plasma using liquid–liquid extraction (LLE). The 
organic extracts were evaporated, reconstituted in mobile phase and injected into the HPLC-MS/MS 
system. The analytes were chromatographed on a XB-C8 analytical column and MS-MS detection was 
performed on an electrospray ionization tandem mass spectrometer operated in multiple reaction 
monitoring (MRM) mode. Precursor→product combinations of m/z 369.9→177.0, 286.3→201.1 and 
285.6→193.1 were used to quantify curcumin, piperine and the internal standard (IS), respectively. The 
assay was validated in the concentration range of 1.0 – 100.0 ng/ml for curcumin and 0.5 – 800.0 ng/ml 
for piperine using 0.5 ml of plasma.  
Results: The lowest limit of quantification (LLOQ) for curcumin and piperine was 1.00 and 0.50 ng/ml, 
respectively. The precision of the assay (expressed as coefficient of variation, CV) was < 12.6 % at all 
concentrations within the standard curve range, with adequate assay accuracy. Stability data revealed 
that the drugs were stable in plasma under various test conditions.  
Conclusion: The method is highly selective and rugged for the estimation of curcumin and piperine in 
human plasma and would be applicable to toxicokinetic, pharmacokinetic, bioavailability, and 
bioequivalence studies. 
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is the major constituent of the yellow spice, 
turmeric, derived from the rhizomes of 
Curcuma spp., which has been reported to 
have a variety of biological activities and 
pharmacological actions, such as anti-tumor, 
anti-inflammatory, anti-virus, anti-oxidation 
and anti-HIV, and low toxicity with promising 
clinical applications [1, 2]. However, curcumin 
is slightly absorbed in the gastrointestinal 
tract (GIT) due to its rapid metabolism by 
conjugation and reduction, and its oral 
bioavailability is very low (only 1 % in rats) [1, 
2]. Pharmacokinetic properties of curcumin 
indicate that following oral administration, it is 
poorly absorbed [1]and only traces of the 
compound appear in the blood, while most of 
it is excreted in the faeces [1]. Piperine, the 
major alkaloidal component of Piper longum 
and Piper nigrum, has been reported to 
enhance the bioavailability of curcumin by 
2000 % in human volunteers [1]. 
 
In view of the potential pharmacological 
effects of curcumin and the possible role of 
piperine in the enhancement of its 
bioavailability, the simultaneous 
determination of these drugs in biological 
matrices can assist in monitoring their 
effectiveness, treatment compliance as well 
as help prevent adverse events and 
formulate optimum dosages.  
 
Several methods have been developed to 
quantify curcumin and piperine individually, 
mainly using HPLC with UV [1-7] and MS 
detectors [1]. A reversed phase HPLC 
method has been reported for simultaneous 
determination of curcumin and piperine in 
human plasma [1]. However, the LOQs 
derived from the methods above were not low 
enough to enable pharmacokinetic study, and 
there has been no report of their 
simultaneous determination by HPLC–
MS/MS. Due to ever increasing demands for 
assays with higher sensitivity, we have 
developed successfully a more sensitive 
liquid chromatography (LC)/tandem mass 
spectrometry (MS/MS) method with a lower 
limit of quantitation (LLOQ) of 1.00 ng/ml for 
curcumin and 0.50 ng/ml for piperine. 
 
The chemical structures of curcumin, piperine 




   









Fig 1: Chemical structures of curcumin, piperine 




Chemicals and reagents 
 
Reference standards of curcumin, piperine 
and diazepam(IS) with purity greater than 
95% were purchased from the National 
Institute for the Control of Pharmaceutical 
and Biological Products (Beijing, China). 
Sulfatase-free β-glucuronidase (type IX-A 
from Escherichia coli) was purchased from 
Sigma (St. Louis, MO). HPLC-grade 
acetonitrile, methyl t-butyl ether (MTBE), 
acetic acid, ammonium acetate and formic 
acid (99 %) were purchased from Tedia 




An LC system (Waters Corporation, Milford, 
Massachusetts) consisting of an Acquity High 
Performance LC and electrospray ionization 
tandem mass spectrometer (ESI-MS/MS; 
Quattro Premier XE, Waters Corporation) 
was used. ESI-MS/MS was performed in the 
positive mode: capillary and cone voltages 
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gas (N2) flow rate was 750 L/h; the ionization 
sources were 120 0C; and the desolvation 
temperature was 400 0C. Multiple-reaction 
monitoring, using the precursor → product 
combination of m/z 369.9→177.0, m/z 
286.3→201.1, m/z 285.6→193.1 was used to 
quantify curcumin, piperine and the internal 
standard (IS, diazepam), respectively. The 
samples were separated on XB-C8 column 
(4.6 × 250 mm, 5μm, Welch Materials, Inc, 
Maryland, USA) using acetonitrile/formic acid 
(0.15%) (60:40, v/v) as the mobile phase. 
The flow rate was 1.0 ml/min, and post-




Curcumin is not stable when pH is greater 
than 7.0 [1]. Therefore, its stock solution 
(50.0 μg/ml) was prepared in acetonitrile-
ammonium acetate buffer (pH 4.5, 0.1M, 
50:50, v/v). This solution was further diluted 
with the buffer to a series of working standard 
solutions (25.0, 125.0 and 1250.0 ng/ml, 
respectively). The stock solution of piperine 
was prepared in acetonitrile–water (50:50, 
v/v), and further diluted to give a series of 
working standards (25.0, 250.0, and 2500.0 
ng/ml, respectively) in acetonitrile-water 
(50:50, v/v). The internal standard (IS, 
diazepam) stock solution (100.0 μg/ml) was 
prepared and further diluted to produce an IS 
working solution (1.0 μg/ml) using 
acetonitrile–water (50:50, v/v). All solutions 
were prepared in amber glassware and 
stored at 4 0C. Due to stability considerations, 
all working standard solutions were prepared 
from the primary stock solution every month.  
 
Preparation of calibration standards and 
test samples  
 
Calibration standards were prepared by 
adding the appropriate volume of each 
working standard to human control plasma to 
obtain a final volume of 500 μl, giving seven 
calibration standards in the range 1.0 - 100.0 
ng/ml for curcumin and eight in the range 0.5 
- 800.0 ng/ml for piperine. Test samples were 
prepared in the same way as the calibration 
standard samples, with the test samples at 
final concentrations of 2.0, 10.0 and 80.0 
ng/ml for curcumin, and 2.0, 30.0 and 500.0 
ng/ml for piperine. All test samples were 
stored at -70 0C until assayed. 
 
Several aliquots of the three fractions were 
stored at −70 0C as controls for future assays 
and used to check short-term stability under 
storage conditions. The analytes were 
considered stable at each concentration 
when the difference between the freshly 
prepared samples and the stability testing 
samples is not more than 15 % of the 
nominal concentration. 
 
Sample preparation  
 
The frozen plasma samples were thawed at 
room temperature, vortexed and centrifuged 
at 12000 rpm for 5 min prior to preparation; 
500 μl of it was aliquoted into a 10-ml 
centrifuge tube and then 100 μl of phosphate 
buffer solution (75 mM; pH 6.8) with 1000U β-
glucuronidase was added. The resulting 
solution was incubated to hydrolyze the 
curcumin conjugates at 37 0C for 1 h. 
Following incubation, the samples were 
spiked with 100 μl of 0.1M ammonium 
acetate buffer (pH 4.5) and 30 μl of IS 
working solution and then extracted with 
methyl-t-butyl ether (5 ml) by rotating mixing. 
The organic extract was transferred to 
another clean 10 ml centrifuge tube and 
evaporated under a stream of nitrogen at 40 
0C. The dried residue was reconstituted in 
100 μl mobile phase. The reconstituted 
samples were vortexed for 30 s and 
centrifuged at 3000 rpm for 5 min, then 10 µl 





The methods were validated for selectivity, 
linearity, intra- and inter-day accuracy, and 
precision. LLOQ, matrix effect, stability of the 
analytes in biological matrix during short- and 
long-term storage and after three freeze–
thaw cycles were also tested. 
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Selectivity of the methods was investigated 
by analysing individual blank plasma samples 
of six donors for endogen interference with 
the analytes. Five calibration standards at 
LLOQ were used as reference samples.   
 
The peak-area ratios of analyte/IS versus the 
nominal concentrations were plotted and a 
least-squares linear regression weighted by 
the reciprocal of the concentration (1/x) was 
applied to generate the calibration curve. 
Test sample concentrations were calculated 
from the regression equation. 
 
LLOQ was defined as the smallest amount of 
the analyte that could be measured in a 
sample with sufficient precision (± 20 %) and 
accuracy (range 80 – 120 %) [1]. Precision 
and accuracy (i.e., ratio of mean actual 
concentration : theoretical concertration 
expressed as a percentage) were evaluated 
on three different days by determining the 
analytes in five replicates of test samples at 
nominal concentrations of 2.0, 10.0 and 80.0 
ng/ml for curcumin, and 2.0, 30.0 and 500.0 
ng/ml for piperine. A standard calibration 
curve was prepared and processed each day 
to analyse the test samples. 
 
The precision of the method at each 
concentration was reported as coefficient of 
variation (CV %), i.e., expressing standard 
deviation as a percentage of the mean 
calculated concentration, while the accuracy 
of the measure was determined by 
expressing the mean calculated 
concentration as percentage of the nominal 
concentration. 
 
Extraction recovery (%) of the two analytes 
was determined in five replicates and at three 
plasma concentrations of the test samples, 
and estimated by comparing peak-area ratios 
of both analytes from extracted plasma 
samples to those from prepared standards.  
 
Plasma matrix effect was tested by 
comparing the chromatographic peak areas 
from neat standards and blank plasma 
extracts spiked with neat standards at three 
concentrations of test samples for curcumin 
and piperine. The stability of the compounds 
was evaluated by analysing test samples in 
triplicate at each concentration level, 
immediately after preparation and after 
leaving 12 h at room temperature or after 
three freeze–thaw cycles in plasma, as well 
as after approximately 2 months of storage at 
−70 0C, In each case, the analytes were 
quantified in the stored samples using a 
freshly prepared calibration curve. 
 
During all the operations, samples were 
protected from light due to the susceptibility 
of curcumin and piperine to photodegradation 




Nine healthy Chinese volunteers were 
recruited. The study was approved by the 
Ethics Committee of the Second Xiangya 
Hospital of Central South University 
(Changsha, China) and informed consent 
was obtained from all subjects. The 
volunteers were instructed not to take any 
drug one week before and during the trials. 
On the trial day, after an 8 h overnight fast, 
600 mg of curcumin plus 20 mg of piperine 
were co-administered and blood samples 
drawn at 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 
48 and 60 h after dosing. Each blood sample 
was collected in a heparinized tube and 
immediately centrifuged. The separated 





Data are reported as mean ± standard 
deviation (SD) for the replicates. The CV (or 
RSD) values and accuracy were calculated 






The analytes were detected in positive 
ionization mode by monitoring their 
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precursor–product combination in multiple 
reaction monitoring (MRM) mode. The 
detecting channels were m/z 369.9→177.0 
m/z for curcumin (channel 2), m/z 
286.3→201.1 m/z for piperine (channel l) and 
m/z 285.6→193.1 m/z for the IS (channel 3). 
The product scan spectra for the protonated 
molecule [M+H]+ of curcumin, piperine and 







Fig 2: The positive ion ESI-MS/MS spectra of curcumin (A), piperine (B) and internal standard (C), 
and their chemical structures 
Selectivity 
 
The elution of the analytes was selective with 
a good separation of peaks in about 8 min 
(curcumin at 5.90 min, piperine 6.64 min and 
IS 6.33 min). Fig 3 shows the representative 
LC-MS/MS chromatograms of blank plasma 
(A), blank plasma spiked with curcumin and 
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sample taken 6 h after oral administration of 
the drugs (C).  
 
Calibration curves and LLOQ 
 
LLOQ, or sensitivity, is defined as the lowest 
concentration on the standard curve that can 
be measured with acceptable precision (≤ 20 
%) and accuracy (≤ 20 % of the nominal 
value)[18]. Based on this method, LLOQ for 
curcumin and piperine were 1.0 and 0.5 
ng/ml, respectively. 
 
The calibration curves showed good linearity and 
acceptable data over a wide range of 
concentrations (1.0 - 100.0 ng/ml for curcumin, 
and 0.50 - 800.0 ng/ml for piperine), with 
regression coefficient (R2) ≥ 0.998. Mean 
accuracy was in the range 81.3 – 119.9 % (at 
LLOQ) for curcumin and between 98.1 and 116.6 
% for piperine. Precision, expressed as CV %, 
was in the range 2.91 - 13.10 % for curcumin and 
0.51 - 11.21 % for piperine. 
 
Precision and accuracy 
 
The accuracy and precision for the analytes 
are shown in Table 1. The method was 
precise and accurate, with intra- and inter-
day CV ≤ 12.36 % and accuracy in the range 
of 94.40 – 108.36 % for curcumin and 94.60 




The results show that the peak area ratio of 
spiked plasma sample to their corresponding 
neat solution ranged from 101.99 to 106.81% 
for both compounds.  
 
Recovery   
 
Mean extraction recovery for curcumin at 2.0, 
10.0 and 80.0 ng/ml was ≥ 85.6 %, with good 
reproducibility indicated by CV% in the range 
2.44 – 6.86 %. Recovery of piperine at 2.0, 
30.0 and 500.0 ng/ml was > 87.4 % with 










Fig 3: Representative chromatograms of (A) blank 
plasma; (B) plasma spiked with curcumin and 
piperine at LLOQ; (C) human plasma sample 
taken 6 h after the oral treatment with the drugs. 
Note: Piperine = channel 1; curcumin = channel 2; 
diazepam = channel 3 
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Table 1: Intra- and inter-day validation of the method for quantitative determination of curcumin and 
piperine 
 
Curcumin theoretical concentration 
(ng/mL) 
Piperine theoretical concentration 
(ng/mL) 
 
2.0 10.0 80.0 2.0 30.0 500.0 
Inter-day       
Day 1       
Mean (n=5) 1.90±0.15 10.84±0.32 81.10±4.25 1.89±0.09 31.15±0.74 491.24±32.33 
CV (%) 8.00 2.92 5.24 4.86 2.37 6.58 
Accuracy (%) 94.90 108.36 101.37 94.60 103.82 98.25 
Day 2       
Mean (n=5) 1.89±0.15 10.00±0.92 79.22±3.92 1.91±0.09 30.92±1.26 496.67±25.29 
CV (%) 8.03 9.22 4.95 4.72 4.06 5.09 
Accuracy (%) 94.60 99.98 99.02 95.30 103.053 99.33 
Day 3       
Mean (n=5) 1.89±0.03 9.66±0.41 79.58±4.16 1.89±0.14 30.52±2.29 494.25±20.91 
CV (%) 1.52 4.19 5.23 7.22 7.50 4.23 
Accuracy (%) 94.40 96.6 99.48 94.60 100.41 98.85 
Intra-day       
Mean (n=15) 1.88±0.09 10.84±0.32 86.10±5.22 1.94±0.24 29.75±1.47 493.54±33.41 
CV (%) 4.74 2.92 6.06 12.36 4.94 6.77 
Accuracy (%) 94.20 108.36 107.62  95.48 100.19 99.75 
 
Short-term stability at room temperature 
 
We evaluated short-term stability in this study 
where three aliquots of each test sample 
were left at room temperature and analysed 
after 12 h. This short-term stability 
experiment revealed no significant degra-
dation for the two compounds in human 
plasma when left at room temperature over a 
period of 12 h, with CV of 2.77 - 6.20 % for 
curcumin and 2.14 - 4.85 % for piperine. 
 
Plasma sample freeze–thaw stability 
 
The results indicate that both curcumin and 
piperine were stable in plasma after three 
freeze–thaw cycles, with CV of 1.64 - 6.12 % 
for curcumin and 1.77 - 5.24 % for piperine. 
 
Long-term stability of frozen plasma at 
−70 0C 
 
Long-term stability was evaluated by 
analyzing the plasma test samples after 
storage at −70 0C for up to 2 months. The 
results showed that both curcumin and 
piperine were stable in the plasma matrix at 
−70 0C for 2 months. For curcumin, the 
accuracy was in the range 99.30 – 100.33 % 
with CV between 2.27 and 7.77 %, while for 
piperine, accuracy and CV were in the range 
97.80 – 102.99 and 1.90 – 5.11 %, 
respectively. 
 
Human plasma levels 
 
Typical chromatograms of clinical samples 
evaluated are shown in Fig 3. The plasma 
concentration profile obtained as a function of 
time following oral dosing of 9 healthy 





















Fig 4: Mean plasma concentration versus time 
profiles of oral administered curcumin( ) 
and piperine( ) in 9 healthy volunteers 
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A sensitive and reliable LC-MS/MS method 
has been developed for the determination of 
curcumin and piperine in human plasma. The 
specificity of the extraction indicate that the 
chromatographic method tested possessed 
the capacity to differentiate and quantitate the 
analyte in the presence of other endogenous 
constituents in samples, as well as to detect 
potential interferences. The analytical 
procedure used was based on liquid–liquid 
extraction to obtain sufficiently high 
recoveries. Significantly lower limit of 
quantitation was achieved in plasma 
compared to previously published methods 
[9,16], with LLOQ as low as 1.0 ng/ml for 
curcumin and 0.5 ng/ml for piperine. No 
interfering peaks were observed and no 
significant peaks were found at the retention 
times of the analytes using the LLE step for 
both analytes.  
 
Since plasma is a complex biological matrix, 
any other endogenous compounds which co-
elute with the analytes may cause ion 
suppression or enhancement, which in turn 
makes the quantitation of the analytes 
inaccurate [3,4]. In the present study, plasma 
matrix effect was tested by comparing 
chromatographic peak areas from neat 
standards and blank plasma extracts spiked 
with neat standards at concentrations of the 
test samples of the two compounds. The 
results obtained showed that the matrix effect 




The HPLC–MS/MS technique presented in 
this work for the simultaneous determination 
of curcumin and piperine in human plasma is 
highly selective and rugged for routine 
measurement of these drugs in combination 
therapy. The results of this study indicate that 
the method would be applicable to 
toxicokinetic, pharmacokinetic, bioavailability, 
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